The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on ...

Measles, one of the world’s most contagious diseases, was declared eliminated in the US in 2000, due to widespread use of the measles-mumps-rubella vaccine.

Increased risk seen in adjusted analyses in association with nucleoside and nucleotide reverse transcriptase inhibitor use.

Recommendations focus on radiation therapy and/or adjunctive therapies for WHO grade 4 adult-type diffuse glioma.

Exposure-response association seen between trihalomethanes and CKD risk; highest risk seen for brominated trihalomethanes.

The FDA is expected to decide on treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis.

The REMS program for the ERA drug class was established due to the risk of embryofetal toxicity seen from animal studies.

The lawsuit was prompted by several recent HHS actions the plaintiffs noted were “designed to mislead, confuse, and gradually desensitize the public to anti-vaccine and anti-science rhetoric.” ...

The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.

The reconstituted panel has not discussed RSV vaccination again and has already caused concern among doctors by questioning proven science around flu vaccines and childhood immunizations.

An analysis of pharmacokinetic data showed ET-600 was bioequivalent to an FDA-approved oral desmopressin product.

The FDA considers the recall “terminated,” meaning it’s no longer active. But officials are urging parents to check their shelves just in case.